Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab
Authors:
- Laura L. SnyderLSLaura L. Snyder
- Jose Maria Garcia-GonzalezJGJose Maria Garcia-Gonzalez
- Michael J. ShapiroMSMichael J. Shapiro
- Michael P. BlairMBMichael P. Blair
- 1 March 2016
- journal article
- case report
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 47 (3) , 280-283
Abstract
The authors report a case of very late reactivation of retinopathy of prematurity (ROP) after bevacizumab monotherapy. A female born at 630 g and 24 weeks received two bilateral treatment of bevacizumab (Avastin; Genentech, South San Francisco, CA) for aggressive posterior ROP (APROP). At 2.5 years of age, ROP reactivated in the form of tractional retinal detachment in one eye and milder reactivation in the other. Although intravitreal bevacizumab treatment is effective in inducing regression of ROP, late reactivation and retinal detachments can occur after initial extended quiescence. Due to alterations of disease progression after bevacizumab, close follow-up by peripheral fluorescein angiography and laser ablation of persistent avascular retina is recommended to prevent disease reactivation and progression to retinal detachment. [ Ophthalmic Surg Lasers Imaging Retina . 2016;47:280–283.]Keywords
This publication has 6 references indexed in Scilit:
- Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from TurkeyGraefe's Archive for Clinical and Experimental Ophthalmology, 2014
- Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser TreatmentJAMA Ophthalmology, 2014
- Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumabJournal of American Association for Pediatric Ophthalmology and Strabismus, 2013
- Reactivation of Retinopathy of Prematurity After Bevacizumab InjectionArchives of Ophthalmology (1950), 2012
- Significant Treatment Failure With Intravitreous Bevacizumab for Retinopathy of PrematurityArchives of Ophthalmology (1950), 2012
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011